The company will not receive any proceeds from the resale or other disposition of the shares of common stock by the selling securityholders.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- BioAtla reports Q1 EPS (26c), consensus (29c)
- BioAtla announces poster presentations at 2025 AACR meeting
- BioAtla price target lowered to $1 from $5 at Citizens JMP
- BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook
- Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside